Simon Beddows

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5688191/publications.pdf

Version: 2024-02-01

69 papers	3,166 citations	159585 30 h-index	155660 55 g-index
70 all docs	70 docs citations	70 times ranked	3810 citing authors

#	Article	IF	Citations
1	Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2015, 15, 565-580.	9.1	556
2	Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet, The, 2013, 382, 1795-1806.	13.7	306
3	Epidemiology ofMycoplasma genitaliumin British men and women aged 16â€“44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). International Journal of Epidemiology, 2015, 44, 1982-1994.	1.9	117
4	Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. Journal of Virology, 2005, 79, 8812-8827.	3.4	115
5	Serotyping HIV Type 1 by Antibody Binding to the V3 Loop: Relationship to Viral Genotype. AIDS Research and Human Retroviruses, 1994, 10, 1379-1386.	1.1	110
6	A Randomized, Observer-Blinded Immunogenicity Trial of CervarixÂ® and GardasilÂ® Human Papillomavirus Vaccines in 12-15 Year Old Girls. PLoS ONE, 2013, 8, e61825.	2.5	103
7	Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 28-33.	2.1	99
8	A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology, 2007, 360, 329-340.	2.4	94
9	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerging Infectious Diseases, 2016, 22, 1732-1740.	4.3	77
10	The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology, 2005, 338, 154-172.	2.4	76
11	Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site. Journal of Virology, 2003, 77, 1084-1091.	3.4	69
12	The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010â€“2016. Journal of Infectious Diseases, 2018, 218, 911-921.	4.0	67
13	Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sexually Transmitted Infections, 2012, 88, 212-217.	1.9	65
14	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine, 2018, 36, 4792-4799.	3.8	60
15	Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ, The, 2012, 344, e4168-e4168.	6.0	57
16	Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine, 2011, 29, 8585-8590.	3.8	56
17	Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open, 2016, 6, e009915.	1.9	54
18	Geographic Diversity of Human Immunodeficiency Virus Type 1: Serologic Reactivity to env Epitopes and Relationship to Neutralization. Journal of Infectious Diseases, 1992, 165, 256-261.	4.0	51

#	Article	IF	Citations
19	Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals. Journal of Virology, 1999, 73, 1740-1745.	3.4	51
20	Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine, 2012, 30, 3867-3875.	3.8	49
21	DNA methylation analysis in liquidâ€based cytology for cervical cancer screening. International Journal of Cancer, 2009, 125, 2995-3002.	5.1	47
22	Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0157976.	2.5	47
23	Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. Journal of Medical Virology, 2003, 70, 337-342.	5.0	42
24	Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer, 2014, 14, 384.	2.6	42
25	Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance: TableÂ1. Sexually Transmitted Infections, 2015, 91, 284-286.	1.9	42
26	Adaptation to Blockade of Human Immunodeficiency Virus Type 1 Entry Imposed by the Anti-CCR5 Monoclonal Antibody 2D7. Virology, 2001, 287, 382-390.	2.4	41
27	Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. Journal of Medical Virology, 2011, 83, 1744-1751.	5.0	40
28	Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. Journal of Antimicrobial Chemotherapy, 2008, 62, 1191-1198.	3.0	38
29	Systemic and Mucosal Immune Responses to Sublingual or Intramuscular Human Papilloma Virus Antigens in Healthy Female Volunteers. PLoS ONE, 2012, 7, e33736.	2.5	36
30	The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. Scientific Reports, 2016, 6, 39730.	3.3	32
31	Trichomonas vaginalis infection is uncommon in the British general population: implications for clinical testing and public health screening. Sexually Transmitted Infections, 2018, 94, 226-229.	1.9	32
32	Longâ€Term Survivors in Nairobi: Complete HIVâ€1 RNA Sequences and Immunogenetic Associations. Journal of Infectious Diseases, 2004, 190, 697-701.	4.0	28
33	Construction and Characterization of Soluble, Cleaved, and Stabilized Trimeric Env Proteins Based on HIV Type 1 Env Subtype A. AIDS Research and Human Retroviruses, 2006, 22, 569-579.	1.1	26
34	High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 842-853.	2.5	26
35	Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either CervarixÂ® or GardasilÂ® vaccine. Vaccine, 2019, 37, 2455-2462.	3.8	26
36	Purified, Proteolytically Mature HIV Type 1 SOSIP gp140 Envelope Trimers. AIDS Research and Human Retroviruses, 2007, 23, 817-828.	1.1	25

#	Article	IF	Citations
37	Cross-neutralizing antibodies elicited by the CervarixÂ® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine, 2014, 32, 1139-1146.	3.8	24
38	Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology, 2006, 351, 121-132.	2.4	22
39	Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine, 2017, 35, 3922-3929.	3.8	21
40	Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines. Infection, Genetics and Evolution, 2013, 18, 151-159.	2.3	19
41	Male Circumcision and STI Acquisition in Britain: Evidence from a National Probability Sample Survey. PLoS ONE, 2015, 10, e0130396.	2.5	19
42	Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. Vaccine Journal, 2012, 19, 449-451.	3.1	17
43	Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. Vaccine, 2014, 32, 6548-6555.	3.8	17
44	Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving CervarixÂ® or GardasilÂ® Vaccine. PLoS ONE, 2015, 10, e0140926.	2.5	17
45	Confirmatory assays are essential when using molecular testing forNeisseria gonorrhoeaein low-prevalence settings: insights from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3): TableÂ1. Sexually Transmitted Infections, 2015, 91, 338-341.	1.9	17
46	Antimicrobial resistance in Mycoplasma genitalium sampled from the British general population. Sexually Transmitted Infections, 2020, 96, 464-468.	1.9	17
47	Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 36-41.	4.5	16
48	Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies. Journal of Infectious Diseases, 2019, 220, 1940-1945.	4.0	15
49	Epidemiology of genital warts in the British population: implications for HPV vaccination programmes. Sexually Transmitted Infections, 2019, 95, 386-390.	1.9	15
50	Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. Journal of Virology, 2016, 90, 3247-3252.	3.4	13
51	Testing for sexually transmitted infections in a population-based sexual health survey: development of an acceptable ethical approach: Table 1. Journal of Medical Ethics, 2012, 38, 380-382.	1.8	12
52	Human papillomavirus type 16 long control region and E6 variants stratified by cervical disease stage. Infection, Genetics and Evolution, 2014, 26, 8-13.	2.3	12
53	Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype. Journal of Virology, 2015, 89, 7748-7757.	3.4	12
54	Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies. Journal of General Virology, 2017, 98, 1755-1761.	2.9	12

#	Article	IF	Citations
55	Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies. Journal of General Virology, 2019, 100, 237-245.	2.9	10
56	Simple detection of point mutations associated with HIV-1 drug resistance. Journal of Virological Methods, 2001, 93, 145-156.	2.1	9
57	Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance. MSphere, 2018, 3, .	2.9	8
58	Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies. Journal of Infectious Diseases, 2018, 218, 1611-1621.	4.0	8
59	Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. Journal of Virology, 2020, 94, .	3.4	7
60	Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120â€“gp41 stability. Virology, 2005, 337, 136-148.	2.4	6
61	Performance of human papillomavirus DNA detection in residual specimens taken for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification testing in men who have sex with men. Sexually Transmitted Infections, 2021, 97, 541-546.	1.9	5
62	Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivity. Journal of General Virology, 2015, 96, 1842-1849.	2.9	4
63	Human papillomavirus (HPV) vaccination and oropharyngeal HPV in ethnically diverse, sexually active adolescents: community-based cross-sectional study. Sexually Transmitted Infections, 2021, 97, 458-460.	1.9	2
64	Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England. Vaccine, 2021, 39, 4210-4218.	3.8	2
65	HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sexually Transmitted Infections, 2021, 97, 382-386.	1.9	2
66	Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7Âyears following immunization with either CervarixÂ® or GardasilÂ® vaccine. Vaccine, 2022, 40, 1198-1202.	3.8	2
67	Sexually active studentsâ€™ acceptability of providing saline oral samples for future human papillomavirus testing. International Journal of STD and AIDS, 2017, 28, 1464-1465.	1.1	1
68	Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay. MethodsX, 2022, 9, 101776.	1.6	1
69	Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies. Microbiology Spectrum, 2022, , e0077922.	3.0	0